

# **CMC Risk-based Product Reviews**

Marshall A. Hayward, Ph.D., Hurley Consulting Associates Ltd.

#### Abstract

Objectives: Ensuring that CMC information is current and appropriate is an important consideration to minimize product risk, especially in regard to legacy products or the divestment and/or acquisition of products. A thorough review supports activities within Regulatory Affairs, QA/QC, and Production, and can provide key data for commercial decision-making.

Methods: The review of CMC submissions and supporting documentation serves several purposes, and is of particular relevance in regard to legacy or in-licensed products. Potential product risks include recalls, out-of-stock situations, or regulatory sanctions. The documentation of the review provides an administrative and legal record to support decisions; can identify problems and remedies; can serve as a reference guide for other reviewers; and, it provides a concise technical information source for Regulatory Affairs, Quality Assurance/Quality Control,

Results: An essential aspect of the review process is to determine if the information is current and appropriate. The starting point for reviews is often the IND or NDA (plus amendments and supplements), annual reports, change control documents the Drug Master File and vendor audits Information in the following areas is reviewed: manufacturing and testing facilities, raw materials, purity, methods validations and stability and batch data, outer packaging labels, and

Conclusions: A properly prepared CMC information summary can prove indispensable when products are divested or acquired. The review will either confirm that information is current and appropriate, or if gaps exist. If informational gaps are identified, solutions to these problem areas are identified and corrective actions taken to minimize risks to product commercialization and continued marketing

## Introduction

Ensuring that CMC information is current and appropriate is an important consideration to minimize product risk, especially for legacy products or the divestment and/or acquisition of products Potential product risks include out-of-stock situations, recalls, or regulatory actions. A thorough review of the CMC information in an application supports activities within Regulatory Affairs. QA/QC, and Production, and can provide key data for mercial decision-making.

The review itself can identify problems and remedies. The documentation of the review provides an administrative, regulatory, and legal record to support decisions; serves as a technical information source for Regulatory Affairs, Quality Assurance/Quality Control, Production, and other disciplines as

The following data are provided for illustrative purposes and serve only to dimensionalize the nature of the approval history for several well-known drugs. This information is available on the following FDA web site:

The site lists all applications for drugs of interest and also characterizes the approval history of individual applications. An



Drug behaved to DANTAC TO (BANTESHE STERROCK), DRIVE (MINTAC TOO, OLANDOMITHOLINE, FOA Application ETHICS)					
Date	-	Tom			
	200	Control Supplement	Labor	_	
11/100		Landing Fluridae	21		
-		Lawrey Revises	Jan St.		
	-	Colonia Service	Auditor		
1000		Chand grown	Audie No.		
1000100	47	State Street	Aber for Production		
	-	District Support	art.		
-11-14		Lambay Services	Average Inc.		
	-	Labeling Streets	Annual State of State		
100		Mondarium Despera notation	Autor to		
		Mandalany Darge e Assista	Aurilla Names		
11/11/11	-	THE I MUTTER HELDER	Labor No.		
	-	Peksy Desp	Laker Ser.		
		Address Street			

Drugs@FDR

Drug products do not remain static; typically, many changes, additions, and revisions to an application are needed over the marketed life of a product. The amount of chemistry. manufacturing, and controls (CMC) and other information in an application is highly variable and depends upon the individual application and unique history of each drug product. As shown in the following table, most drugs have a history of change, particularly if the product has had multiple sponsors.

Type of Approval										
me	Sperce	Normal	Form			Control Transporter	Bridstone	Partiging	Oher/ Box	Total
Deter	40x	160	Terre	1970	- 10	10	-	-	70	
(men menter) (men	See	1007	Talle	27469				1	٠	ø
Merc.	***	1074	Table	01740			*			
Marin (Suprofue) Support	berre	100	Tates	1978				,	٠	н
timeen	Se-sales	160	representati Age A	21621		,			,	18
France	Merce	1665	Terre	Alarmo			1		7	16
(Spec	Tena-	961	76/70	awe		,		,		*
(News	Takes Title	160	topono	perc	w			-		10
(Seein pharuman) (seein)	Aprene	160	hapman	pranti	٠	è		,		19.

The types of information that contribute to compiling a full CMC ition summary, including identification of data sources, the process for conducting a review, and the types of observations that arise from a review are examined in this presentation. In addition, the overall benefits that may result from a rigorous CMC review are described.

# Objectives

- The objectives of the CMC review are as follows . To develop a process to systematically identify available
- . To review the CMC information in order to determine:
- If information is current and appropriate
- If there are problems or gaps

CMC information

- If the Sponsor is in compliance with appli regulations
- To summarize available information, referencing source documents, for ease of retrieval

# Methods

- Step 1: The review is conducted according to established
- Step 2: Data are abstracted and entered into a draft report.
- Sten 3: Abstracted data are checked by Quality Assurance
- Step 4: Data are finalized in a concise report containing tabular summaries.

# Information Reviewed

- esting facilities Suppliers
- Raw materials Analytical methods, methods
- validation, and specifications
- Container/closure systems

- Stability and batch data
- · Outer packaging labels

- Original Application
- Annual Reports
- Production Recon

Sources of Information

- User Fee Lists
- CMC Re-submission
- Annual Product Reviews
- Amendments to submission
- Change Control Records The Drug Master File
- - . Manufacturers, Suppliers, and Testing Facilities Storage Conditions / Expiry Dating

Results

The final document fully characterizes the CMC history of the

product. Information is organized for easy retrieval, in that the

location (i.e., volume/page) of information in the application,

submission dates, and any cross-referencing is tabulated.

The review either confirms that information is current and

appropriate or shows that gaps exist. It also identifies any

. Unresolved legal/regulatory actions directed at the spons

(e.g., 483s, warning letters, establishment inspection

communicated to health authorities (e.g., changes to site;

manufacturing process for active: manufacturing process

· Potential patent problems and related intellectual property

Outstanding reports/protocols from the client or planned

for the client and referred to in the documents planned for

The final CMC information compilation can be categorizing

for product; analytical methods for active; analytical

methods for product; test or process equipment);

Change control process activities that need to be

or the subcontractors referenced in the proposed

current potential compliance issues, such as:

submission

. Pending compliance issues

container/closure suppliers

- Container/Closure Systems
- · Analytical Methods

effectively into four classes

- If CMC informational is inappropriate or gaps are identified during the review, solutions to these problem areas are formulated and corrective actions can be taken to minimize risks to product commercialization and ensure continued marketing.
- An example of a manufacturers, suppliers, and testing facilities summary table is provided below

(may framewow)	Nacracian' Naswor			PERSONAL PROPERTY AND INC.
Occapi Function				
Brief Schallaner I	Facility Months frames	Address	Location in NEW costs, volume, page:	Number
Min Partier	Taplet	THE LIBERT	TOM THE BOTTON BOAT BY NOT UT	THE PARTY
		Chr. Stdn. Za	coverage e. S.	00000
		100,000,00	5-010 debit dei mon-in Appendix 5	
			Approved devinoring.	
			DMF in Province letter	
CR THIRTY WIT	544801	70 tol 730 kg	5.505 March No. 200- of Appendix 5	Supplier 1
Protesse or Grup		Obj. Sten, 2p.	Approved day-fron-yr.	00000
Submirror <sup>6</sup>			(nf authoristion letter	
States, Testing	Supplier 1	Street Address	S. P. E. Ballet Blue Hoth of Apparells S.	Trapped T
(FDN)		CRI. Sten, 29:	Approved devinor-us.	00000
Brug Product TR	Taylor 7	TOWN TARRET	TOMOTHURANI DOS MATON AUTOR	Tarre 7
	Charterly	Oh Ohio Zin	coor letter a. C.A.	00000 Z
	Santry 200	100, 5840, 28	Annual Report deline deciman or	00004
COMME	- meero (201)		CAC AND AND A SELECTION AND A	_
Company			Marchine Court March 1 1 4	
- September			m	
aft	Suppler 1			Supplier 5
Ecoport 1, NF	THE BURNISH			100000
County Shell				
Contacto				
	for evaluation			
	Garder 3		Annual Preson delet deciment a con-	
	Suppley 3		other is a	
Day 100	find acceptable			
humesmen.	NO HARRIS			
159				
OA THISTING WAS	Tracker 1.	Three Address	RYNUE TROOT BEST BUT HON UT.	_
Release of Drug.	(famoly	City, Stoke, Zer	Alfachment 4	
Produit	Supplier 2000			
	Section	Greet Address	COLUMN TO SERVICE STREET	
	Laboratory 17	City, Shake, Zur	Affairments 1.2	
		10, 100, 10	Assertant S. Aur (1).	
			Account Propert delical	
			day monur. Attachment 4	
Steath Seaton		Street Labority	SOM WHITE DEVINE WITH	_
et Drug Product		City, State, Do	Attachments 1, 2	
			Annual Report dated	
			dep-mon-pr, Attachment 4	
Packaging of One Product	CHRAS	Short Address On Shee Jan	STOCKERS IN COLUMN TO STATE AND ADDRESS OF THE PARTY OF T	Core act
Ching Product	Services Cs 1	CRy, Shele, Dar	ASSESSMENT OF THE PARTY OF	Services C
			ARTON CONTRACTOR	
		-		
	Pickage 1	THE RESERVE	STERRESCHOOL MIC	
	Package 1 (ranson shor Package)	THUR ASSESS On Steel, Sa	S.P.S. Sales September 19, Netter, Appropriate desiration of, Annual Papert Sales desiration of, Attachment 4	

## Conclusions

A properly prepared CMC information summary can prove indispensable when issues requiring a rapid response or decision arise. CMC summaries are particularly useful when products are divested or acquired, or if a technology transfer is required. The review will either confirm that information is current and appropriate, or if gaps exist. If informational gaps are identified, solutions to these problem areas are proposed and corrective actions can be taken to minimize risks to product commercialization and continued marketing. In our experience the availability of CMC summaries has allowed quick action to be taken to avoid out of stock situations, to facilitate the preparation

For More Information Please Contact

Marshall A. Hayward, Ph.D. Hurley Consulting Associates Ltd. One Main Street

Chatham, NJ 07928 973-635-9898

mhayward@hurleyconsulting.com or visit him at DIA Booths 1071, 1073

